The analysis of AChE levels in a small sample of AD patients undergoing a clinical trial with the GSK3β inhibitor tideglusib showed a similar but inconclusive tendency since only a minor not statically significant reduction was noticed for P‐tau levels. This evidence concerns the gene MAPT and Alzheimer disease.